menu
    • menu

    Company profile for Samsung Bioepis

    NEW Drugs in Dev: 19
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars.
    Samsung Bioepis is advancing an extensive pipeline of biosimilar candidates through process innovation and an unwavering commitment to quality.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Samsung Bioepiskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    107, Cheomdan-daero, Yeonsu-gu, Incheon
    Telephone
    Telephone
    +82 - 32 - 455 - 6114
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.samsungbioepis.com/en/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/samsung-bioepis
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Samsung Bioepis Report: Biosimilars Surge With 92 US Approvals
    Samsung Bioepis Report: Biosimilars Surge With 92 US Approvals

    28 Apr 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/biopharma/biosimilars-gain-momentum-as-us-market-sees-92-approvals-samsung-bioepis-report-19950

    INDPHARMAPOST
    28 Apr 2026
    Share Share
    Samsung Bioepis Releases Q2 2026 U.S. Biosimilar Report
    Samsung Bioepis Releases Q2 2026 U.S. Biosimilar Report

    27 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260427670459/en/Samsung-Bioepis-Releases-Second-Quarter-2026-US-Biosimilar-Market-Report

    BUSINESSWIRE
    27 Apr 2026
    Share Share
    Samsung Epis Holdings Unveils Q1 2026 Financial Performance
    Samsung Epis Holdings Unveils Q1 2026 Financial Performance

    23 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-23/samsung-epis-holdings-reports-first-quarter-2026-financial-results

    PHARMIWEB
    23 Apr 2026
    Share Share
    Samsung Bioepis Reveals Preclinical Data For ADC SBE303 At AACR
    Samsung Bioepis Reveals Preclinical Data For ADC SBE303 At AACR

    21 Apr 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/biopharma/samsung-bioepis-unveils-promising-preclinical-data-for-novel-adc-sbe303-at-aacr-2026-19838

    INDPHARMAPOST
    21 Apr 2026
    Share Share
    Samsung Bioepis Shows SBE303 ADC Preclinical Data at AACR
    Samsung Bioepis Shows SBE303 ADC Preclinical Data at AACR

    20 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260420507268/en/Samsung-Bioepis-Presents-Nonclinical-Data-for-its-First-Novel-Antibody-Drug-Conjugate-Candidate-SBE303-at-AACR-2026

    BUSINESSWIRE
    20 Apr 2026
    Share Share
    Samsung Bioepis Shows SB16 Denosumab Consistency at WCO 2026
    Samsung Bioepis Shows SB16 Denosumab Consistency at WCO 2026

    17 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260416509744/en/Samsung-Bioepis-Highlights-Consistent-Efficacy-of-SB16-OBODENCE-Denosumab-Across-Osteoporosis-Patient-Subgroups-at-WCO-IOF-ESCEO-2026

    BUSINESSWIRE
    17 Apr 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search